Literature DB >> 2729719

Xylazine and tiletamine-zolazepam anesthesia in horses.

J A Hubbell1, R M Bednarski, W W Muir.   

Abstract

The cardiopulmonary and anesthetic effects of xylazine in combination with a 1:1 mixture of tiletamine and zolazepam were determined in 6 horses. Each horse was given xylazine IV or IM, as well as tiletamine-zolazepam IV on 4 randomized occasions. Anesthetics were administered at the rate of 1.1 mg of xylazine/kg of body weight, IV, 1.1 mg of tiletamine-zolazepam/kg, IV (treatment 1); 1.1 mg of xylazine/kg, IV, 1.65 mg of tiletamine-zolazepam/kg, IV (treatment 2); 1.1 mg of xylazine/kg, IV, 2.2 mg of tiletamine-zolazepam/kg, IV (treatment 3); and 2.2 mg of xylazine/kg, IM, 1.65 mg of tiletamine-zolazepam/kg, IV (treatment 4). Tiletamine-zolazepam doses were the sum of tiletamine plus zolazepam. Xylazine, when given IV, was given 5 minutes before tiletamine-zolazepam. Xylazine, when given IM, was given 10 minutes before tiletamine-zolazepam. Tiletamine-zolazepam induced recumbency in all horses. Duration of recumbency in group 1 was 31.9 +/- 7.2 (mean +/- 1 SD) minutes. Increasing the dosage of tiletamine-zolazepam (treatments 2 and 3) significantly (P less than 0.05) increased the duration of recumbency. Xylazine caused significant (P less than 0.05) decreases in heart rate and cardiac output and significant (P less than 0.05) increases in central venous pressure and mean pulmonary artery pressure 5 minutes after administration. Respiratory rate was decreased. Arterial blood pressures increased significantly (P less than 0.05) after xylazine was administered IV in treatments 1 and 3, but the increases were not significant in treatment 2. Xylazine administered IM caused significant (P less than 0.05) increases in central venous pressure and significant (P less than 0.05) decreases in cardiac output.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2729719

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  7 in total

1.  A comparison of romifidine and xylazine when used with diazepam/ketamine for short duration anesthesia in the horse.

Authors:  C L Kerr; W N McDonell; S S Young
Journal:  Can Vet J       Date:  1996-10       Impact factor: 1.008

2.  Cardiopulmonary effects of romifidine/ketamine or xylazine/ketamine when used for short duration anesthesia in the horse.

Authors:  Carolyn L Kerr; Wayne N McDonell; Simon S Young
Journal:  Can J Vet Res       Date:  2004-10       Impact factor: 1.310

3.  Modification of cardiopulmonary and intestinal motility effects of xylazine with glycopyrrolate in horses.

Authors:  S Singh; S S Young; W N McDonell; M O'Grady
Journal:  Can J Vet Res       Date:  1997-04       Impact factor: 1.310

4.  [Intravenous anesthesia in the horse: comparison of xylazine-ketamine and xylazine-tiletamine-zolazepam combinations].

Authors:  S Cuvelliez; G Rosseel; D Blais; Y Salmon; E Troncy; N Larivière
Journal:  Can Vet J       Date:  1995-10       Impact factor: 1.008

5.  Ketamine, Telazol, xylazine and detomidine. A comparative anesthetic drug combinations study in ponies.

Authors:  H C Lin; K R Branson; J C Thurmon; G J Benson; W J Tranquilli; W A Olson; A T Vähä-Vahe
Journal:  Acta Vet Scand       Date:  1992       Impact factor: 1.695

6.  Immobilization of Captive Kulans (Equus hemionus kulan) Without Using Ultrapotent Opioids.

Authors:  Julia Bohner; Johanna Painer; Denyse Bakker; Anna Jean Haw; Hanna Rauch; Eva Maria Greunz; Beate Egner; Frank Goeritz
Journal:  Front Vet Sci       Date:  2022-08-10

7.  A fixed moderate-dose combination of tiletamine+zolazepam outperforms midazolam in induction of short-term immobilization of ball pythons (Python regius).

Authors:  Lynn J Miller; David P Fetterer; Nicole L Garza; Matthew G Lackemeyer; Ginger C Donnelly; Jesse T Steffens; Sean A Van Tongeren; Jimmy O Fiallos; Joshua L Moore; Shannon T Marko; Luis A Lugo-Roman; Greg Fedewa; Joseph L DeRisi; Jens H Kuhn; Scott J Stahl
Journal:  PLoS One       Date:  2018-10-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.